Ultima Markets[Market Hotspot] Modena's earnings exceeded expectations last quarter, leading to an increase in stock price

Thursday, ModenaModerna (MRNA.US) The stock price surged significantly as the company announced quarterly profits that surprised Wall Street. The COVID-19 vaccine manufacturer announced that its revenue in the fourth quarter reached 28 Billion US dollars, earnings per share 0.55 USD, breaking FactSet Analysts predict25 Revenue of billions of dollars and per share0.99 USD loss.

Chief Financial OfficerJamey Mock This unexpected profit result is partly due to 6 Due to deferred income of billions of dollars. Moderna Continue to fulfill the promise of reducing expenses and see results. The cost of selling goods last year was47 Billion US dollars, lower than estimated 50 USD100mn

Nevertheless, such as Moderna The financial report revealed that the company's sales in the fourth quarter decreased compared to the same period last year45%The main cause of decline is the company's Covid-19 Vaccine sales have declined. Correspondingly, profits also face challenges85%The decline of.

2023Throughout the fiscal year,ModernaRevenue is68Billion US dollars, a decrease from the previous year64%Loss per share12.33USD, compared to2022Annual earnings per share20.12The US dollar forms a sharp contrast.

Moderna Currently focused onmRNA Technological development of other drugs to seek new opportunities, including human respiratory fusion virus(RSV)Vaccines to challenge major competitor Pfizer (PFE.US) Glaxosmithkline plc (GSK.US) Developed vaccines

After the financial report is released,Moderna The stock price skyrocketed 13.5% to 99.44 USD. As for forward-looking guidance,Moderna Reiterating estimates 2024 Annual sales revenue 40 Billion US dollars, and R&D costs reach45 USD100mn

(ModernaAnnual chart of stock price performance)

Disclaimers

The comments, news, research, analysis, pricing, and other information contained in this article can only be considered as general market information and are provided solely to assist readers in understanding the market situation and do not constitute investment advice.Ultima MarketsReasonable measures have been taken to ensure the accuracy of the data, but the accuracy of the data cannot be guaranteed and can be changed at any time without notice.UltimaMarketsWe will not be responsible for any losses or losses (including but not limited to any loss of profits) that may arise from the direct or indirect use or reliance on such information.